Investment Research Firm Maintains 'Hold' Rating on Qiagen Stock | GenomeWeb
NEW YORK (GenomeWeb News) – Zacks Investment Research issued a research note on Wednesday maintaining its “hold” rating on Qiagen’s stock and setting a six-month price target of $24 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.